ESTRO 2024 - Abstract Book

S2291

Clinical - Urology

ESTRO 2024

Conclusion:

Routinely-collected health data support the trial findings of similar long-term GU and GI morbidity after UHF and CF RT in localised PCa. Excess GU and GI morbidity related to prostate RT as defined in our study ranged between 3% and 10% at 10 years compared to a matched group without PCa. We found no excess mortality from the GU or GI conditions.

Keywords: ultra-hypofractionation, prostate cancer

References:

[1] Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394:385 – 95. https://10.1016/S0140 6736(19)31131-6.

15

Digital Poster

Toxicity & QoL after IMRT of oligometastatic prostate carcinoma: systematic evaluation after 15years

Bettina Hentschel, Dirk Strauß, Katharina Berger, Dorn Uta